U.S. Markets close in 5 hrs 31 mins

Free Technical Insights on CASI Pharma and Three Other Biotech Stocks

Stock Research Monitor: AVDL, CDMO, and BPMC

LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on CASI sign up now at www.wallstequities.com/registration. On Wednesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.89%; the Dow Jones Industrial Average edged 1.26% higher; and the S&P 500 was up 1.27%. US markets made broad based gains with all sectors finishing the day in green. Pre-market today, WallStEquities.com reviews these four Biotechnology stocks: Avadel Pharmaceuticals PLC (NASDAQ: AVDL), Avid Bioservices Inc. (NASDAQ: CDMO), Blueprint Medicines Corp. (NASDAQ: BPMC), and CASI Pharmaceuticals Inc. (NASDAQ: CASI). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration


Avadel Pharmaceuticals

Dublin, Ireland headquartered Avadel Pharmaceuticals PLC's stock finished Wednesday's session 3.56% higher at $6.69. A total volume of 273,392 shares was traded. The Company's shares have advanced 0.90% in the past month. The stock is trading below its 50-day moving average by 4.58%. Furthermore, shares of Avadel Pharma, which develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the US, France, and Ireland, have a Relative Strength Index (RSI) of 47.02. Get the full research report on AVDL for free by clicking below at:

www.wallstequities.com/registration/?symbol=AVDL


Avid Bioservices

Shares in Tustin, California-based Avid Bioservices Inc. ended at $3.23, down 4.44% from the last trading session. The stock recorded a trading volume of 194,589 shares. The Company's shares have gained 31.30% over the previous three months. The stock is trading below its 50-day moving average by 1.88%. Moreover, shares of Avid Bioservices, which operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture, have an RSI of 38.36. CDMO's complimentary research coverage is a few simple steps away at:


www.wallstequities.com/registration/?symbol=CDMO


Blueprint Medicines

Cambridge, Massachusetts headquartered Blueprint Medicines Corp.'s stock ended yesterday's session 1.21% higher at $82.50 with a total trading volume of 227,324 shares. The Company's shares have advanced 133.38% in the last twelve months. The stock is trading above its 200-day moving average by 9.58%. Additionally, shares of Blueprint Medicines, which develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease, have an RSI of 50.04. Are you already registered with Wall St. Equities? Do so now for free, and get the report on BPMC at:

www.wallstequities.com/registration/?symbol=BPMC


CASI Pharmaceuticals

On Wednesday, shares in Rockville, Maryland headquartered CASI Pharmaceuticals Inc. recorded a trading volume of 232,487 shares. The stock finished the day 2.50% higher at $6.55. The Company's shares have advanced 89.31% in the previous three months and 568.37% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 1.96% and 79.62%, respectively. Furthermore, shares of CASI Pharma, which focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China, have an RSI of 46.20. Aspiring Member, please take a moment to register below for your free research report on CASI at:

www.wallstequities.com/registration/?symbol=CASI

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

  • Hedge Funds Are Buying Adtalem Global Education Inc. (ATGE)
    Business
    Insider Monkey

    Hedge Funds Are Buying Adtalem Global Education Inc. (ATGE)

    In this article we look at what those investors think of Adtalem Global Education Inc. NYSE:ATGE). Adtalem Global Education Inc.

  • Is LendingTree, Inc (TREE) A Good Stock To Buy ?
    Business
    Insider Monkey

    Is LendingTree, Inc (TREE) A Good Stock To Buy ?

    Hedge funds' top 3 stock picks returned 41.7% this year and beat the S&P 500 ETFs by 14 percentage points. Investing in index funds guarantees you average returns, not superior returns. We are looking to generate superior returns for our readers.

  • Merck drops $2.7B on 26-year-old Burlington biotech
    Business
    American City Business Journals

    Merck drops $2.7B on 26-year-old Burlington biotech

    Drug giant Merck & Co. announced Monday that it will spend billions to buy a 26-year old biotech company that's struggled to bring a cancer drug to market. Merck (NYSE: MRK) will spend approximately $2.7 billion to acquire Burlington-based ArQule Inc. (Nasdaq: ARQL). The biotech's drug that's furthest along in clinical trials is in the mid-stage tests against relapsed or refractory chronic lymphocytic leukemia.

  • Business
    GuruFocus.com

    My Bunny Portfolio Has Been Limping, Not Hopping

    When will my Bunny Portfolio show some energy? To be eligible, a stock must have an average earnings growth rate of 25% or better the past five years, and yet sell for 12 times earnings or less. GuruFocus has detected 6 Warning Signs with WLH.

  • Should You Buy Portola Pharmaceuticals Inc (PTLA)?
    Business
    Insider Monkey

    Should You Buy Portola Pharmaceuticals Inc (PTLA)?

    We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017.

  • Is Solaredge Technologies Inc (SEDG) Going To Burn These Hedge Funds ?
    Business
    Insider Monkey

    Is Solaredge Technologies Inc (SEDG) Going To Burn These Hedge Funds ?

    Seeing as Solaredge Technologies Inc (NASDAQ:SEDG) has experienced bearish sentiment from hedge fund managers, it's safe to say that there is a sect of money managers that slashed their full holdings in the third quarter. Intriguingly, Anthony Bozza's Lakewood Capital Management dumped the biggest investment of the "upper crust" of funds tracked by Insider Monkey, worth an estimated $10.3 million in stock, and Steve Cohen's Point72 Asset Management was right behind this move, as the fund dumped about $4.4 million worth. These bearish behaviors are important to note, as aggregate hedge fund interest fell by 3 funds in the third quarter.

  • Did Hedge Funds Drop The Ball On Clovis Oncology Inc (CLVS) ?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On Clovis Oncology Inc (CLVS) ?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). Clovis Oncology Inc (NASDAQ:CLVS) has seen a decrease in support from the world's most elite money managers recently. CLVS was in 20 hedge funds' portfolios at the end of September.

  • Did Hedge Funds Drop The Ball On Teva Pharmaceutical Industries Limited (TEVA) ?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On Teva Pharmaceutical Industries Limited (TEVA) ?

    That's why we believe it isn't a waste of time to check out hedge fund sentiment before you invest in a stock like Teva Pharmaceutical Industries Limited (NYSE:TEVA). Is Teva Pharmaceutical Industries Limited (NYSE:TEVA) undervalued? Prominent investors are selling.

  • 2 Children in North Carolina Charged With Involuntary Manslaughter
    U.S.
    Meredith Videos

    2 Children in North Carolina Charged With Involuntary Manslaughter

    Authorities in North Carolina say they've charged an 11-year-old boy and a 12-year-old girl with involuntary manslaughter after they got into a physical altercation with another child who was struck by a vehicle and killed

  • Did Hedge Funds Drop The Ball On Nutanix, Inc. (NTNX)?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On Nutanix, Inc. (NTNX)?

    Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish on. One of their picks is Nutanix, Inc.

  • Hedge Funds Have Never Been This Bullish On Kontoor Brands, Inc. (KTB)
    Business
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Kontoor Brands, Inc. (KTB)

    That's why we weren't surprised when hedge funds' top 20 large-cap stock picks generated a return of 37.6% in 2019 (through the end of November) and outperformed the broader market benchmark by 9.9 percentage points.This is why following the smart money sentiment is a useful tool at identifying the next stock to invest in. Kontoor Brands, Inc. NYSE:KTB) investors should pay attention to an increase in hedge fund interest lately.

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of SSI earnings conference call or presentation 21-Nov-19 1:30pm GMT

    As a result, our end of the third quarter excess availability under our credit facility was over $100 million and the increase of approximately $35 million compared to the second quarter and our highest quarter end level in almost 2 years. Our comp store increase of 17% demonstrates that our strategic initiatives are clearly working. While there were multiple drivers of our outstanding sales performance, the most important for our future is the sales lift we are delivering in the stores converted from department stores to off-price.

  • Is The Macerich Company (MAC) Going To Burn These Hedge Funds ?
    Business
    Insider Monkey

    Is The Macerich Company (MAC) Going To Burn These Hedge Funds ?

    We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017.

  • Tullow CEO Quits Amid Poor Production
    Business
    Bloomberg

    Tullow CEO Quits Amid Poor Production

    Tullow Oil Plc's CEO and exploration director quit after a slew of operational setbacks, marking the exit of the old guard. Bloomberg's Will Kennedy reports on “Bloomberg Markets: European Open.

  • Hedge Funds Are Dumping Texas Roadhouse Inc (TXRH)
    Business
    Insider Monkey

    Hedge Funds Are Dumping Texas Roadhouse Inc (TXRH)

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. Texas Roadhouse Inc (NASDAQ:TXRH) investors should be aware of a decrease in hedge fund sentiment of late. TXRH was in 22 hedge funds' portfolios at the end of September.

  • What Is Baidu, Inc.'s (NASDAQ:BIDU) Share Price Doing?
    Business
    Simply Wall St.

    What Is Baidu, Inc.'s (NASDAQ:BIDU) Share Price Doing?

    Today we're going to take a look at the well-established Baidu, Inc. (NASDAQ:BIDU). The company's stock saw a decent share price growth in the teens level on the NASDAQGS over the last few months. Today I will analyse the most recent data on Baidu's outlook and valuation to see if the opportunity still exists.

  • Did Hedge Funds Drop The Ball On Immunomedics, Inc. (IMMU) ?
    Business
    Insider Monkey

    Did Hedge Funds Drop The Ball On Immunomedics, Inc. (IMMU) ?

    IMMU was in 20 hedge funds' portfolios at the end of September. There were 21 hedge funds in our database with IMMU positions at the end of the previous quarter. Video: Click the image to watch our video about the top 5 most popular hedge fund stocks.

  • Three Things You Should Check Before Buying Gilead Sciences, Inc. (NASDAQ:GILD) For Its Dividend
    Business
    Simply Wall St.

    Three Things You Should Check Before Buying Gilead Sciences, Inc. (NASDAQ:GILD) For Its Dividend

    Could Gilead Sciences, Inc. (NASDAQ:GILD) be an attractive dividend share to own for the long haul? On the other hand, investors have been known to buy a stock because of its yield, and then lose money if the company's dividend doesn't live up to expectations. With a five-year payment history and a 3.8% yield, many investors probably find Gilead Sciences intriguing.

  • World's largest biotech company to move up to BioMed's big South City project
    Business
    American City Business Journals

    World's largest biotech company to move up to BioMed's big South City project

    Amgen Inc. will move more than 600 employees into a nine-story, 240,000-square-foot building in the Gateway of Pacific project in South San Francisco in early 2022, becoming the second major biotech company to secure space in the under-construction BioMed Realty development. The deal caps a search of more than a year by Amgen (NASDAQ: AMGN) to replace lab and office space at Oyster Point Boulevard and Veterans Boulevard — an eight-minute walk away from Gateway of Pacific — which since 2014 has been the Bay Area research-and-development home for the world's largest biotech company. Terms of the transaction were not disclosed, but leases in the South San Francisco biotech hub over the past year have run upwards of $65 per square foot.

  • Is Banco Santander, S.A.  (SAN) A Good Stock To Buy?
    Business
    Insider Monkey

    Is Banco Santander, S.A. (SAN) A Good Stock To Buy?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Conversely, hedge funds' top 20 large-cap stock picks generated a return of 37.4% during the same 11-month period, with the majority of these stock picks outperforming the broader market benchmark.

  • Here’s What Hedge Funds Think About NovoCure Limited (NVCR)
    Business
    Insider Monkey

    Here’s What Hedge Funds Think About NovoCure Limited (NVCR)

    Hedge funds' top 3 stock picks returned 41.7% this year and beat the S&P 500 ETFs by 14 percentage points. Investing in index funds guarantees you average returns, not superior returns. We are looking to generate superior returns for our readers.

  • Hedge Funds Have Never Been This Bullish On New York Community Bancorp, Inc. (NYCB)
    Business
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On New York Community Bancorp, Inc. (NYCB)

    SEC filings and hedge fund investor letters indicate that the smart money seems to be paring back their overall long exposure since summer months, though some funds increased their exposure dramatically at the end of Q3 and the beginning of Q4. In this article, we analyze what the smart money thinks of New York Community Bancorp, Inc. (NYSE:NYCB) and find out how it is affected by hedge funds' moves. NYCB was in 23 hedge funds' portfolios at the end of September.

  • Is NetApp Inc. (NTAP) A Good Stock To Buy ?
    Business
    Insider Monkey

    Is NetApp Inc. (NTAP) A Good Stock To Buy ?

    Since stock returns aren't usually symmetrically distributed and index returns are more affected by a few outlier stocks (i.e. At the same time, the 20 most favored S&P 500 stocks by the hedge funds monitored by Insider Monkey generated an outperformance of more than 8 percentage points so far in 2019. Of course, hedge funds do make wrong bets on some occasions and these get disproportionately publicized on financial media, but piggybacking their moves can beat the broader market on average.

  • Is Cracker Barrel Old Country Store, Inc. (CBRL) Going to Burn These Hedge Funds?
    Business
    Insider Monkey

    Is Cracker Barrel Old Country Store, Inc. (CBRL) Going to Burn These Hedge Funds?

    Cracker Barrel Old Country Store, Inc. NASDAQ:CBRL) was in 21 hedge funds' portfolios at the end of September. CBRL investors should be aware of a decrease in hedge fund interest of late.

  • Is Molson Coors Brewing Company (TAP) A Good Stock To Buy?
    Business
    Insider Monkey

    Is Molson Coors Brewing Company (TAP) A Good Stock To Buy?

    That's why we scrutinize hedge fund sentiment before we invest in a stock like Molson Coors Brewing Company (NYSE:TAP). Is Molson Coors Brewing Company (NYSE:TAP) the right investment to pursue these days? Hedge funds are reducing their bets on the stock.